High blood pressure, or hypertension, often goes unnoticed but can lead to severe health issues like heart attack and stroke.

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose hypertension is either uncontrolled by or resistant to existing medicines.

Endocrine Society experts encouraged more widespread screening for a common hormonal cause of high blood pressure known as ...

Delayed diagnosis of hypertension after initial elevated BP measurement was tied to lower rates of antihypertensive drug ...

The drug came to AstraZeneca through its acquisition of CinCor Pharma in 2023, with the hopes of beefing up its ...

Researchers found a 30% increased risk of cardiovascular events in patients whose diagnosis was delayed by more than a year ...

AstraZeneca's new drug, baxdrostat, has successfully lowered blood pressure in a late-stage trial for treatment-resistant ...

Investigators studied whether changes in renal hyperfiltration status affects patient outcomes using a Korean population cohort of more than 4.5 million patients.

Research shows that the damage from high blood pressure often happens slowly over many years. A study published in the New ...

To tackle the issue of high salt consumption, the NIE has launched a three-year intervention project in Punjab and Telangana, ...

One in three adults in the U.S. has three or more risk factors for a newly recognized but increasingly common condition: ...